Here's why Granules India shares could see a reaction on Monday

What happened

Granules India said the US FDA completed a current Good Manufacturing Practice inspection at its finished-dosage facility in Gagillapur, Hyderabad, from October 19 to October 30, 2026. The regulator issued Form 483 with 11 observations, and the company said the inspection had concluded.

Confirmed

Global impact / market context

Form 483 observations identify practices that an FDA investigator believes may violate drug-safety rules or risk product quality. If the issues require corrective work or disrupt production, Granules could face higher costs or delays in making and selling medicines from the facility.

Analyst inference

The article says Granules shares will be in focus on Monday, November 2, after the inspection result was reported. The 11 observations are confirmed, but the supplied text gives no company response, remediation details, production impact, or share-price reaction.

Analyst inference

What to watch

1. Look for Granules’ full response to the 11 Form 483 observations; the supplied article says the company was contacted, but its reaction is cut off before details appear. Confirmed
2. Watch for Granules’ explanation of the 11 observations and any corrective steps it reports, since actions to address inspection findings could shape the facility’s regulatory outlook. Analyst inference
3. Check for later company disclosures about the Gagillapur inspection or its outcome, which could clarify whether the 11 observations lead to operational changes at the Hyderabad facility. Analyst inference

Evidence

• Original source link unavailable